Background: Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to recognize and eliminate malignant cells. Over the past decade, immune checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and combination immunotherapeutic approaches have transformed the management of multiple solid tumors. Significant improvements in survival outcomes have been reported in malignancies previously associated with poor prognoses, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, hepatocellular carcinoma, and head and neck cancers.

Objective: This review evaluates the clinical outcomes of immunotherapy in solid tumors, focusing on survival benefits, response rates, prognostic biomarkers, treatment-related adverse events, and future directions in immuno-oncology.

Methods: A narrative review of contemporary clinical trials, meta-analyses, and international oncology guidelines was conducted. Data regarding overall survival (OS), progression-free survival (PFS), objective response rates (ORR), disease control rates (DCR), and quality-of-life outcomes were synthesized.

Results: Immunotherapy has demonstrated durable clinical responses and prolonged survival across various solid tumors. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 pathways have shown significant efficacy, particularly in tumors with high mutational burden or elevated PD-L1 expression. Combination therapies have further enhanced outcomes in selected patient populations. However, immune-related adverse events and treatment resistance remain major clinical challenges.

Conclusion: Immunotherapy has fundamentally altered the treatment paradigm for solid tumors. Ongoing advances in biomarker-guided treatment selection, combination strategies, personalized medicine, and cellular therapies are expected to further improve clinical outcomes and expand the benefits of immunotherapy to broader patient populations.